Jones Day (Washington)

Larissa C. Bergin

Jones Day (Washington)

Larissa Bergin is a partner with Jones Day in Washington. Her practice addresses the antitrust concerns arising from M&A matters, joint ventures, federal investigations, and commercial practices. She has overseen the antitrust aspects of corporate M&A, including due diligence, risk-shift negotiations, Hart-Scott-Rodino (HSR) filings, Second Requests, investigational hearings, integration planning, and consent decrees with federal agencies. She works with clients in a variety of industries, including the technology, health care, retail, and pharmaceutical sectors. Many of Larissa’s clients have international reach, and she has been involved in matters that require advocacy before governments throughout Asia, the EU, and North America.


Linked authors

Jones Day (Sydney)
Jones Day (Mexico)
Jones Day (Brussels)
Jones Day (New York)
Jones Day (Madrid)


977 Bulletin

Sarah A. Geers, Jonathan Berman, Larissa C. Bergin, Rosanna McCalips, Ryan C. Thomas The US Court of Appeals for the Fifth Circuit rules that showing that the reverse payment settlement eliminated the possibility of an earlier generic entry is enough to infer anticompetitive effects (Endo / Impax)


In Short The Background: In the Supreme Court’s landmark 2013 decision in FTC v. Actavis, the Court determined that large payments by branded drugmakers to potential generic entrants to settle patent disputes could be anticompetitive. It instructed district courts to apply the "rule of reason" (...)

Tiffany D. Lipscomb-Jackson, Aimee E. DeFilippo, Debra R. Belott, Larissa C. Bergin, Thilini Chandrasekera, Amanda Vaughn The US Senate introduces proposed antitrust reform legislation titled the Competition and Antitrust Law Enforcement Reform Act of 2021 (CALERA)


This article has been nominated for the 2022 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards Antitrust reform has become a popular topic in the halls of Congress, academia, and even some (socially distant) gatherings. The topic has slowly picked up pace (...)

Michael H. Knight, Geoffrey D. Oliver, Larissa C. Bergin The US Court of Appeals for the Third Circuit limits the FTC’s ability to seek damages for past conduct in a pharmaceutical patent abuse case (Shire Viropharma)


In Short The Situation: The United States Court of Appeals for the Third Circuit ruled that the FTC could not recover past profits under FTC Act Section 13(b) if the alleged violation occurred in the past and the defendant was not "violating" or "about to violate" the law. The Impact: The (...)

Jonathan Berman, Rosanna McCalips, Julia E. McEvoy, Larissa C. Bergin The US Congress implements a law requiring drug manufacturers to disclose biologic patent settlement agreements to antitrust Authorities


New Law Requires Disclosure of Biologic Patent Settlement Agreements to Antitrust Authorities* Last week, the Patient Right to Know Drug Prices Act ("Act") became law. The Act requires pharmaceutical companies to disclose to antitrust agencies agreements between biologic and biosimilar (...)

Send a message